Our top pick for
24/5 trading
Gilead Sciences Inc (GILD) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$87.75. During the previous open market day, the price has varied from a low of USD86.08 to a high of USD88.6. Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Gilead Sciences
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$87.75, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Have Gilead Sciences's shares ever split?
Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Gilead Sciences shares at a glance
Information last updated 2024-11-15.
| 52-week range | US$60.7503 - US$98.9 |
|---|---|
| 50-day moving average | US$86.4892 |
| 200-day moving average | US$74.7907 |
| Target price | US$94.615 |
| PE ratio | 1023.4444 |
| Dividend yield | US$3.06 (3.34%) |
| Earnings per share (TTM) | US$0.09 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Gilead Sciences price performance over time
Historical closes compared with the last close of $87.75
| 1 week (2024-11-13) | -5.27% |
|---|---|
| 1 month (2024-10-18) | 1.19% |
| 3 months (2024-08-20) | 17.39% |
| 6 months (2024-05-20) | 29.23% |
| 1 year (2023-11-20) | 15.46% |
|---|---|
| 2 years (2022-11-18) | 4.94% |
| 3 years (2021-11-19) | 27.75% |
| 5 years (2019-11-20) | 35.25% |
Compare trading platforms to buy Gilead Sciences shares
1 - 4 of 26
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Gilead Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gilead Sciences share price volatility
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$60.7503 up to US$98.9. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.192. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences financials
| Revenue TTM | US$28.3 billion |
|---|---|
| Operating margin TTM | 41.96% |
| Gross profit TTM | US$21.6 billion |
| Return on assets TTM | 11.96% |
| Return on equity TTM | 0.56% |
| Profit margin | 0.45% |
| Book value | 14.827 |
| Market capitalisation | US$114.8 billion |
| EBITDA | US$13.9 billion |
TTM: trailing 12 months
Gilead Sciences share dividends
Dividend payout ratio: 69.53% of net profits
Recently Gilead Sciences has paid out, on average, around 69.53% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.34% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 3.34% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3.06 per share.
Gilead Sciences's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Gilead Sciences's most recent dividend payout was on 26 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 12 December 2024 (the "ex-dividend date").
Gilead Sciences's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Gilead Sciences's total ESG risk score
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Gilead Sciences's environmental score
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.15 |
|---|---|
| Total ESG percentile | 30.98 |
| Environmental score | 0.53 |
| Environmental score percentile | 2 |
| Social score | 12.97 |
| Social score percentile | 2 |
| Governance score | 7.65 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Gilead Sciences overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences in the news
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
Frequently asked questions
More resources on Finder
More guides on Finder
-
Online investing in Australia: Stat and facts 2023
We analyse the growth of online investment platforms in Australia.
-
The best ASX penny stocks (updated weekly)
Big gainers included SelfWealth, Metal Hawk and Island Pharmaceuticals.
-
Best performing stocks on the ASX (Updated weekly)
Top gainers included PYC Therapeutics, Fineos Corporation Holdings and Weebit Nano.
-
Australian Ethical managed funds review: Options, features and fees
A wealth management company that will appeal to ESG investors.
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
How to invest in Nasdaq from Australia
Find out how you can invest in Nasdaq and compare a range of leading brokers that let you invest in US stocks cheaply and quickly.
-
How to invest in index funds in Australia
Index funds are a hot topic right now, but how do you actually invest in them?
-
Best investment and stock trading apps in Australia (2024)
Compare share trading apps to find out which app has all the tools and resources you need to reach your investment goals.
-
14 best share trading platforms Australia – ranked
Follow these tips to find the best share trading platform for you.
-
How to buy shares in Australia in 2024
Learn everything you need to know in this easy to follow, step-by-step guide to buying shares in Australia.
Ask a question